Page last updated: 2024-10-26

dup 697 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

dup 697 has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

DuP 697: structure given in first source

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Peng, HL1
Zhang, GS1
Liu, JH1
Gong, FJ1
Li, RJ1

Other Studies

1 other study available for dup 697 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation.
    Annals of hematology, 2008, Volume: 87, Issue:2

    Topics: Apoptosis; Bone Marrow Cells; Caspase 8; Cell Cycle; Cyclooxygenase 2 Inhibitors; Dose-Response Rela

2008